TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models
Cleveland Clinic · Cerner (United States) · +5 more institutions
Abstract
Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer's disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2's involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45(hi)Ly6C(+) myeloid cells, but not on P2RY12(+) parenchymal microglia. In AD mice deficient for TREM2, the CD45(hi)Ly6C(+) macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for…
Citation impact
- FWCI
- 43.43
- Percentile
- 100%
- References
- 34
Authors
20- TRTaylor R. Jay
Cleveland Clinic, Cerner (United States), Lou Ruvo Brain Institute, Case Western Reserve University
- CMCrystal M. Miller
Cleveland Clinic, Cerner (United States), Lou Ruvo Brain Institute
- PJPaul J. Cheng
Cleveland Clinic, Cerner (United States), Lou Ruvo Brain Institute, Case Western Reserve University
- LGLeah Graham
Jackson Laboratory
- SMShane M. Bemiller
Cleveland Clinic, Kent State University, Cerner (United States), Lou Ruvo Brain Institute
Topics & keywords
- TREM2
- Microglia
- Neurodegeneration
- Inflammation
- Pathogenesis
- Alzheimer's disease
- Disease
- Macrophage
- Good health and well-being